PNC-27

PNC-27 is a laboratory-designed peptide studied only in cell cultures and animal models, never in humans. It combines a fragment of the p53 tumor-suppressor protein with a cell-penetrating sequence called penetratin, and is engineered to bind a protein called HDM-2 on the surface of cancer cell membranes, punching pores in them and killing the cells through necrosis rather than the more common process of programmed cell death.

Ask about PNC-27

Research snapshot

Peptide categorySynthetic p53-derived / penetratin chimeric peptide (preclinical research compound)
Primary research interestSelective cancer-cell killing via HDM-2 binding at the cancer-cell plasma membrane
Highest available evidencePublished cell-culture research and limited mouse xenograft work, mostly from the group that created the peptide. No published human data
Human research availableNo. PNC-27 has not been tested in humans, and ClinicalTrials.gov lists no registered study
Development statusPreclinical academic research compound; not in any known clinical development pipeline
Regulatory statusNot approved anywhere. No registered trial or public IND was identified. Covered by a patent filing, not a regulatory pathway

Technical identity

Primary namePNC-27
Alternative namesNone widely used; related compound PNC-28 is a distinct sequence from the same research program
Peptide sequenceH-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH
Amino-acid length32 residues
Molecular formulaNot reliably established from authoritative chemical databases
Molecular weightNot reliably established from authoritative chemical databases
CAS Registry NumberNo verified CAS Registry Number could be identified from authoritative chemical databases
PubChem CIDNo verified PubChem CID could be identified from authoritative chemical databases
UNIINot established
DrugBank IDNot established
Chemical modificationsFusion of a p53 HDM-2-binding fragment with the penetratin cell-penetrating peptide sequence
Peptide classp53-derived / penetratin chimeric peptide
Primary biological targetHDM-2 (MDM2 homolog) presented on the plasma membrane of cancer cells
Developer or originatorAcademic research program (Roswell Park Cancer Institute-affiliated research)
Development statusPreclinical only

What it is

PNC-27 is a synthetic, chimeric 32-residue peptide (reported sequence: H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH) built from two functional parts: a segment corresponding to the HDM-2-binding region of the p53 tumor-suppressor protein, and the “penetratin” sequence, a well-known cell-penetrating peptide originally derived from the Drosophila Antennapedia homeodomain. It was designed and characterized by researchers (notably groups associated with Kalinski, Sarafraz-Yazdi, and Pincus at New York Medical College) beginning in the mid-2000s, building on earlier work with a related peptide, PNC-28.

The rationale behind PNC-27 rests on the observation that HDM-2 (the human analog of murine MDM2, a natural inhibitor of p53) is overexpressed not just inside the nucleus of many cancer cells but also on their outer plasma membrane, a feature that appears far less common in normal, non-cancerous cells. PNC-27 was designed to exploit this by binding membrane-associated HDM-2 directly, rather than by working through the intracellular p53 pathway the way many other p53-related cancer therapeutics attempt to. This gives it a proposed mechanism of selective toxicity toward cancer cells that display surface HDM-2, largely sparing normal cells that lack it.

PNC-27 is exclusively a preclinical research compound. It has been evaluated in numerous cancer cell lines (including pancreatic, breast, melanoma, and leukemia lines) and in some animal tumor models, but it has not entered human clinical trials, has no registered clinical development program identified in this review, and is not an approved or investigational new drug in any regulatory sense. It should be understood strictly as an early-stage academic research tool rather than a drug candidate with clinical-stage evidence.

How does it work?

Plain-English explanation

Many cancer cells display a protein called HDM-2 on their outer surface, something healthy cells mostly do not do. PNC-27 is built to latch onto that surface protein and then punch a hole in the cancer cell’s outer membrane, causing the cell to burst and die quickly (necrosis) rather than dying through the body’s normal, more controlled cell-death process (apoptosis). Because it targets a feature specific to the cancer cell’s outer membrane, researchers hope it could kill tumor cells while leaving normal cells largely undamaged.

Technical explanation

Structural and biochemical studies indicate that the C-terminal residues of PNC-27 (roughly corresponding to the p53-derived segment) fold into a conformation resembling the native p53-HDM-2 binding interface, allowing PNC-27 to bind membrane-associated HDM-2 in cancer cells. Rather than being internalized and degraded, the peptide is reported to adopt an alpha-helix-loop-alpha-helix structure that inserts into and remains within the cancer cell plasma membrane, where it forms pores, causing membranolysis and necrotic cell death. This is described as distinct from classical apoptotic pathways and appears to depend specifically on the target cell expressing HDM-2 in its plasma membrane, since untransformed cell lines lacking surface HDM-2 have shown much lower sensitivity in reported experiments. Reported in vitro IC50 values (the concentration that kills half the cells) have ranged from about 6 to 80 µM across cancer cell lines, per the originating group’s 2024 review. These are cell-culture concentrations and do not translate to any human dose.

Potential benefits and research applications

Selective cancer cell killing (preclinical)

What is being investigated: whether PNC-27 can selectively kill cancer cells that express surface HDM-2 while sparing normal cells. How the effect might occur: membrane-pore formation following HDM-2 binding, as described above. Evidence: cell-culture studies across several cancer cell lines (pancreatic, breast, melanoma, leukemia) reporting cytotoxic and necrotic effects, plus some tumor-regression findings referenced from work in nude mice, including a leukemia study and a pancreatic tumor study described in the originating group’s 2024 review, using PNC-27 and its shorter relative PNC-28 over two to three weeks. Strength: Tier 3-4 (animal and laboratory/mechanistic evidence only; no human data). Limitation: no human trials exist, dosing and pharmacokinetics in a whole living human body are unknown, and translation from cell culture and mouse models to human efficacy and safety cannot be assumed.

p53-independent tumor targeting

What is being investigated: whether PNC-27’s membrane-based mechanism can kill cancer cells regardless of whether their own intracellular p53 gene is mutated or functional, a potential advantage since many tumors have lost normal p53 function. How the effect might occur: because PNC-27 acts at the cell membrane on HDM-2 rather than requiring intracellular p53 signaling, it is proposed to work even in p53-mutant or p53-null cancer cells. Evidence: reported in laboratory cell-line studies. Strength: Tier 4, mechanistic/laboratory only. Limitation: this remains a hypothesis supported by in vitro observations, not confirmed in any human or advanced in vivo efficacy setting.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
Cancer-cell killing in cell cultureAdded to culture mediumIC50 values of about 6 to 80 µM across cancer lines (12.4 µM in one cervical line, 60 µM for complete killing of primary ovarian cancer cells)Single exposure15 minutes to 24 hours, with 4 hours typicalLaboratory research (Pincus 2024 review, Krzesaj 2025)
Mouse xenograft (patent example)Injected, route not specifiedTotal of 1, 10, 20, 30, or 50 mg per mouseSchedule not stated14 daysPatent or developer documentation (US 12,239,720), not peer reviewed
Nude-mouse leukemia and pancreatic tumor studiesDaily intraperitoneal injection (PNC-27, leukemia) or intraperitoneal minipump infusion (PNC-28, pancreatic)Amount not stated in the review that describes themDaily, or continuous infusion3 weeks (leukemia), 2 weeks (pancreatic)Published animal research. Pancreatic study: Michl 2006 (PNC-28, nude mice, 2 weeks, intraperitoneal; amount not in the abstract). Leukemia study: known only from the Pincus 2024 review, primary paper not retrieved
Self-directed human useSubcutaneous (as listed by one educational site)200 to 300 mcg, and separately 1 to 5 mg3 times weekly, and dailyNot establishedOrigin unclear: community quick-reference with no source
Administered human use, any routeNot applicableNo established or reliably sourced dosing information was identifiedNot applicableNot applicableNone identified

Amounts studied in human research

No established or reliably sourced dosing information was identified. PNC-27 has not been studied in humans; there is no human clinical dosing data of any kind.

Amounts studied in animal research

Research objectiveSpecies or modelAmount studiedFrequencyDurationRouteSource
Tumor growth, subcutaneous xenograftsNu/Nu mice, 20 to 22 g, 10 per groupTotal of 1, 10, 20, 30, or 50 mg per mouseNot stated14 daysInjected, route not specifiedUS patent 12,239,720, Example 8
Metastatic pancreatic tumor (PNC-28)Nude mice, TUC-3 rat pancreatic cancer cellsNot stated in the reviewContinuous infusion2 weeksIntraperitoneal minipumpPincus 2024 review of earlier work
Human acute myeloid leukemia (PNC-27)Nude mice with patient-derived AML cells (9 patients)Not stated in the reviewDaily3 weeksIntraperitoneal injectionPincus 2024 review of a City of Hope study

Both tables above are animal figures and cannot be converted into a human amount. The review by the originating group says the pancreatic tumors were eradicated after two weeks of PNC-28, the treated mice gained weight like untreated controls, and PNC-27 normalized white cell counts and prolonged survival in the leukemia model. The same group wrote the review, two of its authors are affiliated with a company (NomoCan), and I could not retrieve the primary mouse papers, so the per-dose amounts in those two studies are unconfirmed. Cell-culture exposure is reported in micromolar concentrations (about 6 to 80 µM IC50) rather than a dose.

Practitioner and community-reported protocols

PNC-27 is sold by research-chemical vendors, and some educational and community sites publish self-administration numbers. One educational site lists a “maintenance” figure of 200 to 300 mcg subcutaneously three times a week and an “aggressive research” figure of 1 to 5 mg daily, but cites no source for either and states on the same page that no human dosing study or standardized animal protocol exists. Origin unclear. A personal account on a Substack describes injecting PNC-27 near a tumor site and adjusting the dose over time but gives no numbers. These are Tier 6 sources and are not evidence of safety or effectiveness.

What circulates E5

PNC-27 is sold by some research-chemical and peptide vendors and discussed in online communities with informally suggested self-administration protocols. These figures are widely repeated online, but their original source could not be verified.

Given that PNC-27 has never been tested in a living human being in any clinical setting, no such community-reported protocol should be interpreted as having any established safety or efficacy basis, and no specific amount was consistent enough across sources to responsibly tabulate here.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Side effects, risks, and limitations

Because PNC-27 has no human trial history, there is no characterized human side-effect profile. The originating group’s review reports that treated mice gained weight like untreated controls and showed no evidence of off-target effects, but that is the authors’ own summary, I could not retrieve the primary toxicology data, and mouse tolerability does not predict human safety. Its proposed mechanism, forming pores that cause necrosis (a less controlled kind of cell death than apoptosis), raises a theoretical concern about inflammation or tissue damage if HDM-2 is present on the surface of some non-cancerous cells, and how selective it is in a whole organism is unproven. Material sold as “PNC-27” also carries the general risks of unregulated peptides: uncertain purity, incorrect concentration, contamination, and no sterility assurance. Self-administering a compound with no human safety data carries risks that cannot be quantified from the preclinical literature.

Regulatory and developmental status

PNC-27 is not approved by FDA or any other regulator for any use. A ClinicalTrials.gov search on October 8, 2026 found no registered study of it, and no public Investigational New Drug application was identified. It was created and developed by an academic group at SUNY Downstate (New York) with a related company, NomoCan Pharmaceuticals, named in author affiliations. A US patent (12,239,720) covers methods using PNC-27 or PNC-28 in acute myeloid leukemia, which is a patent position and not a regulatory step. It is best classed as an experimental laboratory tool.

Frequently asked questions

What is PNC-27?

It is a synthetic, laboratory-designed peptide combining a p53-derived HDM-2-binding fragment with the penetratin cell-penetrating sequence, studied preclinically for its ability to selectively kill cancer cells that express HDM-2 on their outer membrane.

Has PNC-27 been tested in humans?

No. All available evidence comes from cell-culture studies and a few mouse xenograft studies, mostly from the group that created the peptide. ClinicalTrials.gov lists no registered human study.

How does PNC-27 kill cancer cells?

It binds HDM-2 protein present on the outer surface of many cancer cells and is reported to form pores in the cell membrane, causing the cell to die by necrosis rather than by the more typical apoptosis pathway.

What dosage has been studied?

No human dose has been studied. In animals, a patent describes total amounts of 1 to 50 mg per mouse over 14 days, and the originating group describes daily intraperitoneal injections for 3 weeks in a leukemia model without giving the amount in its review. Cell-culture work uses concentrations of roughly 6 to 80 µM. None of these can be converted into a human dose.

Is PNC-27 the same as PNC-28?

No, though they are related compounds from the same research program; PNC-28 is a separate peptide sharing the penetratin cell-penetrating sequence, studied in some of the same laboratories for related but distinct anticancer mechanisms.

Is PNC-27 approved or in clinical trials?

No. It is an unapproved, preclinical-only research compound with no identified registered human trial.

Is it safe to use?

This has not been established in humans at all. With zero human safety data, no dose can be considered established as safe.

What remains unknown?

Whether PNC-27’s cancer-cell selectivity seen in cell culture and limited animal models would hold up in a living human, what a safe or effective human dose might be, and whether the necrosis-inducing mechanism would produce unacceptable toxicity in vivo, are all unresolved questions with no clinical data to answer them.

Bottom line

PNC-27 is a scientifically interesting preclinical peptide with an unusual proposed mechanism: binding HDM-2 on the cancer cell membrane and forming pores that cause necrosis. The evidence is cell culture, a few mouse studies, and a patent, most of it from the group that developed it, and independent replication was not identified. No human dosing information exists. The only human-use numbers found, 200 to 300 mcg three times weekly and 1 to 5 mg daily SC, come from an educational site that cites no source and contradicts itself on the same page, so treat them as unverified. PNC-27 is not approved, has no registered trial, and should be understood as a laboratory research tool, not a therapeutic option.

Sources

  1. PNAS (2010) study describing PNC-27 structure, HDM-2-binding conformation, and membrane-pore-forming mechanism; primary source for the mechanism description and general characterization of PNC-27 in this entry. PMID 20080680
  2. Full-text version of the PNAS 2010 paper; source for the reported PNC-27 amino acid sequence, cell lines tested (MIA-PaCa-2, MCF-7, A-2058, TUC-3 cancer lines vs. MCF-10-2A, AG13145, BMRPA1 non-cancer lines), in vitro concentration ranges, and the note that prior related work described tumor regression in nude mice. PMC2836618
  3. Study extending PNC-27 cytotoxicity findings to a leukemia (non-solid tumor) cell line, supporting the claim that its HDM-2-membrane-dependent mechanism has been demonstrated across multiple cancer cell types, still entirely at the cell-culture level. PMID 25117093
  4. Later structural study reinforcing the p53-penetratin chimeric design and membrane-pore mechanism of PNC-27; used to corroborate the mechanism and chimeric composition described in this entry. PMID 35625682
  5. Pincus MR, Silberstein M, Zohar N, Sarafraz-Yazdi E, Bowne WB. Poptosis or peptide-induced transmembrane pore formation: a novel way to kill cancer cells without affecting normal cells. Biomedicines. 2024;12(6):1144. Review by the originating research group; two authors are affiliated with NomoCan. DOI 10.3390/biomedicines12061144
  6. Krzesaj PK, Seydafkan S, Miller AI, et al. HDM-2-targeting peptide PNC-27 kills cervical cancer cells but not normal cervical cells. Ann Clin Lab Sci. 2025;55(3):347-353. Cell-culture study. PMID 40750238
  7. Krzesaj P, Adler V, Feinman RD, et al. Anti-cancer peptide PNC-27 kills cancer cells by unique interactions with plasma membrane-bound HDM-2 and with mitochondrial membranes causing mitochondrial disruption. Ann Clin Lab Sci. 2024;54(2):137-148. Cell-culture study. PMID 38802154
  8. USPTO. Compositions for use in lysis of selective cancer cells. National stage of PCT/US2019/026390 (priority US 62/653,808, April 6, 2018). Example 8 describes mouse xenograft dosing of PNC-27 and PNC-28 (total 1 to 50 mg per mouse over 14 days, route stated only as injected). Patent document, not peer-reviewed. US 12239720; PCT/US2019/026390
  9. Peptide Protocol Wiki. PNC-27 dosing. Quick-reference box lists 200-300 mcg three times weekly SC and 1-5 mg daily SC with no source; the same page states no human dosing data or standardized in vivo protocol exists. Community/educational source, Tier 6. peptideprotocolwiki.com/peptides/pnc27/dosing
  10. Personal account describing PNC-27 injected near a tumor site, dose started low and adjusted. States no numeric dose, frequency or duration. Anecdotal, Tier 6. therubyprotocol.substack.com
  11. ClinicalTrials.gov interventional-trial search on the intervention name PNC-27, run October 8, 2026, returned no registered studies. Search term PNC-27, checked 2026-10-08
  12. Michl J, Scharf B, Schmidt A, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006;119(7):1577-1585. PMID 16688716

Research area: Immune and thymic.

Share thisFacebookXEmail